Innate Immunotherapy
“Innovate with Purpose”
Transforming the landscape of the treatment ecosystem for patients with liver disease
AuroraCell was founded on a vision, a vision to build a global biotechnology startup. Following results from the initial discovery research the technology now aims to transform the way in which doctors treat patients with liver cirrhosis (end stage liver disease). AuroraCell will treat the underlying disease as opposed to purely treating symptoms with the ultimate goal of enabling disease resolution and longevity.
Immunotherapy has significantly advanced cancer treatment however it is our aim to use immunotherapy to address mechanisms of fibrotic diseases, starting with the liver. AuroraCell is a biotechnology start up with its technology in the preclinical proof of concept research stage and dedicated to bring the concept to fruition.
AuroraCell is targeting the innate immune system through its novel technology. It is set on doing things a little differently and forging a new path in the world of immunotherapy. Rather than do things the typical way, we’re creating a technology designed around our patients’ needs and the sharp rise in a disease in a younger demographic.
A Novel Approach
Our Products
Cytofinity
CYTOFINITY will be an innate immunotherapy treatment which will be infused into patients in a clinic setting. It will target patients with end stage liver disease and in the longer term aims to remove the need for transplant by stimulating liver regeneration.
Future
In the future Cytofinity could be applied to other diseases starting with other fibrotic diseases like lung fibrosis and could even transition out to a range of other diseases such as various cancers.
Connect with us.
If you are interested in a collaboration or an investment or anything in between, please connect with us here.
Fill out the form with your information and we’ll be in touch shortly.